Randomized trial of oxaliplatin plus S-1 (SOX) versus S-1 alone in patients with gemcitabine-refractory pancreatic cancer

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220660

Enrollment

240

Registered

2009-01-23

Start date

2009-01-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gemcitabine-refractory pancreatic cancer

Interventions

investigational material(s) Generic name etc : Oxaliplatin and S-1 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma Gemcitabine refractory Taking orally ECOG performance status (PS) :0-1 Measurable metastatic disease based on RECIST criteria

Exclusion criteria

Exclusion criteria: Prior treatment with platinum- or fluoropyrimidine -agent Prior treatment with radiotherapy

Design outcomes

Primary

Measure	Time frame
Progression free survival (PFS) To verify the superiority of SOX to S-1 alone in PFS	—

Secondary

Measure	Time frame
Overall survival, response rate, safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026